Companies
Medigene
MDG1015 is a first-in-class, third-generation TCR construct, with the company's broader pipeline (MDG3020, MDG3010) extending its TCR platform.
- Country
- Germany
- Ticker
- MDG
3rd-gen TCR-T (MDG1015)
Coverage
| CN | EU | US | |
|---|---|---|---|
| therapeutics-platforms | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Funding | Raised EUR 5.9 million in May 2024; secured a standby equity purchase agreement for up to EUR 15 million in October 2024 | medigene.com · biospace.com |
| Capacity | Six-day manufacturing process developed for TCR-T therapies, producing an almost pure CD8+ population with ~95% stem-like qualities medium confidence | synapse.patsnap.com |
| Certification | No specific ISO or manufacturing certifications mentioned; holds patents for lead program MDG1015 components | medigene.com |
| Regulatory approval | FDA IND clearance received in Q3 2024 for MDG1015; CTA submission to EMA in Q4 2024 | medigene.com |
| Production site | Located at Lochhamer Strasse 11, 82152 Martinsried, Germany | marketscreener.com |
| Revenue | EUR 1.4 million in Q3 2024; trailing 12-month revenue of $8.06 million as of June 30, 2024 | medigene.com |
Independent sources: biospace.com · marketscreener.com · synapse.patsnap.com
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| TCR therapy (T-cell receptor engineered T cells) | therapeutics-platforms | Low | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.